Versartis Inc. (VSAR) Shares Down 1.7%
Shares of Versartis Inc. (NASDAQ:VSAR) were down 1.7% during mid-day trading on Friday . The company traded as low as $11.31 and last traded at $11.56, with a volume of 125,835 shares. The stock had previously closed at $11.76.
A number of analysts have recently issued reports on VSAR shares. Canaccord Genuity reiterated a “buy” rating on shares of Versartis in a report on Monday, April 4th. Northland Securities assumed coverage on Versartis in a report on Thursday, April 7th. They issued an “outperform” rating for the company. Zacks Investment Research cut Versartis from a “buy” rating to a “hold” rating in a report on Wednesday, April 20th. Morgan Stanley restated a “hold” rating on shares of Versartis in a report on Saturday, April 30th. Finally, Credit Suisse Group AG restated a “sell” rating and issued a $9.00 price target on shares of Versartis in a report on Friday. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $16.60.
The firm has a 50-day moving average price of $10.87 and a 200-day moving average price of $9.34. The company’s market capitalization is $339.12 million.
Versartis (NASDAQ:VSAR) last announced its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.03. On average, equities analysts forecast that Versartis Inc. will post ($3.09) earnings per share for the current year.
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.